Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
SAGE Sage Therapeutics	$9.20 +1.3%	$7.50	$4.62 ▼ $13.47	$575.79M	0.29	1.30 million shs	3.01 million shs
SUPN Supernus Pharmaceuticals	$32.00 -0.2%	$32.26	$25.66 ▼ $40.28	$1.79B	0.7	477,192 shs	212,566 shs
VYGR Voyager Therapeutics	$3.28 +2.5%	$3.22	$2.65 ▼ $9.55	$181.52M	0.85	481,437 shs	303,242 shs
XENE Xenon Pharmaceuticals	$34.70 +4.0%	$32.54	$26.74 ▼ $46.00	$2.66B	1.1	630,958 shs	492,450 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
SAGE Sage Therapeutics	+1.27%	-0.92%	+40.81%	+34.04%	-13.42%
SUPN Supernus Pharmaceuticals	-0.23%	+2.55%	-0.73%	-2.28%	+23.01%
VYGR Voyager Therapeutics	+2.50%	+10.44%	0.00%	+6.15%	-57.57%
XENE Xenon Pharmaceuticals	+4.00%	+7.78%	+12.97%	+18.04%	-3.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
SAGE Sage Therapeutics	3.2244 of 5 stars	2.0	2.0	4.0	2.3	1.7	0.6
SUPN Supernus Pharmaceuticals	2.5737 of 5 stars	2.2	2.0	4.1	2.1	0.0	0.0
VYGR Voyager Therapeutics	3.6874 of 5 stars	3.6	1.0	4.6	1.1	0.8	0.6
XENE Xenon Pharmaceuticals	3.3237 of 5 stars	4.5	2.0	0.0	2.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
SAGE Sage Therapeutics	2.00	Hold	$8.93	-2.85% Downside
SUPN Supernus Pharmaceuticals	2.33	Hold	$36.00	12.52% Upside
VYGR Voyager Therapeutics	3.13	Buy	$13.39	308.23% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$54.82	57.96% Upside

Current Analyst Ratings Breakdown

Latest XENE, SUPN, SAGE, and VYGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/14/2025	XENE Xenon Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
5/13/2025	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $47.00
5/13/2025	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00
5/13/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
SAGE Sage Therapeutics	$41.24M	13.96	N/A	N/A	$7.60 per share	1.21
SUPN Supernus Pharmaceuticals	$661.82M	2.71	$4.16 per share	7.69	$18.76 per share	1.71
VYGR Voyager Therapeutics	$80M	2.27	N/A	N/A	$5.49 per share	0.60
XENE Xenon Pharmaceuticals	$9.43M	282.38	N/A	N/A	$9.90 per share	3.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)
SUPN Supernus Pharmaceuticals	$73.86M	$1.11	28.82	22.22	N/A	9.27%	12.23%	9.17%	8/5/2025 (Estimated)
VYGR Voyager Therapeutics	-$65M	-$1.46	N/A	N/A	N/A	-126.49%	-27.36%	-21.06%	8/5/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$234.33M	-$3.23	N/A	N/A	N/A	N/A	-32.44%	-30.84%	8/14/2025 (Estimated)

Latest XENE, SUPN, SAGE, and VYGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	N/A	N/A	N/A	$16.69 million	N/A
5/12/2025	Q1 2025	XENE Xenon Pharmaceuticals	-$0.90	-$0.83	+$0.07	-$0.83	$1.64 million	$7.50 million
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
SAGE Sage Therapeutics	N/A	9.13	9.13
SUPN Supernus Pharmaceuticals	N/A	2.44	2.26
VYGR Voyager Therapeutics	N/A	6.10	6.10
XENE Xenon Pharmaceuticals	N/A	17.66	17.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
SAGE Sage Therapeutics	99.22%
SUPN Supernus Pharmaceuticals	N/A
VYGR Voyager Therapeutics	48.03%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
SAGE Sage Therapeutics	5.50%
SUPN Supernus Pharmaceuticals	8.80%
VYGR Voyager Therapeutics	6.39%
XENE Xenon Pharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
SUPN Supernus Pharmaceuticals	580	55.99 million	51.06 million	Optionable
VYGR Voyager Therapeutics	100	55.34 million	51.80 million	Optionable
XENE Xenon Pharmaceuticals	210	76.73 million	72.50 million	Optionable

XENE, SUPN, SAGE, and VYGR Headlines

Recent News About These Companies

Xenon Appoints CEO Ian Mortimer as Interim CFO

July 3 at 6:32 PM | tipranks.com

Xenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution - Nasdaq

June 29, 2025 | nasdaq.com

Xenon Pharmaceuticals Joins Russell 3000® and 2000® Indexes

June 27, 2025 | tipranks.com

Xenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution

June 27, 2025 | quiverquant.comQ

Xenon Joins the Russell 3000® and Russell 2000® Indexes

June 27, 2025 | financialpost.comF

Xenon Joins the Russell 3000® and Russell 2000® Indexes

June 27, 2025 | globenewswire.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 26, 2025 | financialpost.comF

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 26, 2025 | globenewswire.com

Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)

June 26, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Share Price Passes Below 50 Day Moving Average - What's Next?

June 25, 2025 | marketbeat.com

Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

June 24, 2025 | globenewswire.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Down 3.4% - Here's Why

June 16, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from Analysts

June 15, 2025 | marketbeat.com

Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

June 12, 2025 | marketbeat.com

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

June 11, 2025 | zacks.com

Cantor Fitzgerald Estimates XENE FY2026 Earnings

June 10, 2025 | marketbeat.com

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025 | globenewswire.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 30, 2025 | globenewswire.com

Fair Value analysis proves accurate as XENE drops 37% from February 2024 peak

May 21, 2025 | investing.com

Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday

May 15, 2025 | insidermonkey.com

Polarean's Xenon MRI technology to feature in over 30 studies at American Thoracic Society events

May 15, 2025 | proactiveinvestors.co.uk

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE, SUPN, SAGE, and VYGR Company Descriptions

Sage Therapeutics NASDAQ:SAGE

$9.20 +0.12 (+1.27%)

Closing price 07/3/2025 02:52 PM Eastern

Extended Trading

$9.20 0.00 (0.00%)

As of 07/3/2025 04:28 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Supernus Pharmaceuticals NASDAQ:SUPN

$32.00 -0.08 (-0.23%)

Closing price 07/3/2025 01:31 PM Eastern

Extended Trading

$32.00 0.00 (0.00%)

As of 07/3/2025 04:07 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Voyager Therapeutics NASDAQ:VYGR

$3.28 +0.08 (+2.50%)

Closing price 07/3/2025 03:33 PM Eastern

Extended Trading

$3.20 -0.07 (-2.29%)

As of 07/3/2025 04:44 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Xenon Pharmaceuticals NASDAQ:XENE

$34.70 +1.33 (+4.00%)

As of 07/3/2025 02:52 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time